Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Identification and Characterization of Novel Tyrosine Kinase InhibitorsTargeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]
Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in HumanLeukemia Cell Lines [Abstract # 2270]
Identification of a Novel Class of Nonpeptidyl Small-Molecule Inhibitorsof the Human Proteasome [Abstract # 3271]
Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer DrugDiscovery at Telik [Abstract # 4754]
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA, a modified glutathione analogfor the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP, which enables the rapid and efficient discovery of small molecule drugcandidates.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks orregistered trademarks of Telik, Inc.Inhibition of the vascular endothelial growth factor receptor signaling pathway with antibodies or small molecules has been proven effective as an anti-cancer therapy. Through the use of Telik's Target-Related Affinity Profiling (TRAP(R)) screening technology, novel inhibitors of VEGFR2 kinase were discovered. The inhibitors belong to nine structural classes, among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase.
SOURCE Telik, Inc.
You May Also Like